RxDoctor Payments Data

Nakita Helligar, APRN

Gerontology · Kissimmee, FLNPI 1184114829

Payments from drug & device makers

$1,405in general payments, 2019–2025

Across 42 payments — averaging $33.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$882
  • Lilly USA, LLC$239
  • Eisai Inc.$229
  • Microtransponder, Inc.$36
  • Boston Scientific$19

What the payments were for

  • Food & beverage$1,405100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie35$882
Lilly USA, LLC3$239
Eisai Inc.2$229
Microtransponder, Inc.1$36
Boston Scientific1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,405 in reported general payments places this provider in the 70th percentile of 714 gerontology providers in Florida.

See all gerontology providers in Florida

Medicare billing

Part B allowed, 2024
$53,742
Medicare patients
230
Services billed
429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Memantine Hcl469$11,161
Rivastigmine31$6,163
Donepezil Hcl255$5,316
Memantine Hcl ErMemantine Hcl57$4,202
RivastigmineRivastigmine Tartrate50$3,434
Quetiapine Fumarate113$1,935
Mirtazapine63$1,909
Buspirone Hcl99$1,714
Galantamine ErGalantamine Hbr11$1,600
Sertraline Hcl204$1,307
Escitalopram Oxalate115$1,240
Galantamine Hbr11$809
Olanzapine12$575
Citalopram HbrCitalopram Hydrobromide33$423
Risperidone11$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$239$57512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 714 gerontology providers in Florida.

Other gerontology in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →